Ceres Pharma acquires Dacia Plant
Ceres Pharma, a Belgian based dynamic and fast growing pharmaceutical company, active in Women’s and Family healthcare, has come to an agreement for the acquisition of the Romanian firm Dacia Plant.
The acquisition of Dacia Plant is an important step in the further development of Ceres Pharma in Central and Eastern Europe.
Dacia Plant is one of the pioneers and a top 3 player in Romania active in the development, production and distribution of qualitative and innovative natural food supplements and vitamins. Dacia Plant is a very known, strong and trusted company among doctors, pharmacists and patients in Romania with a wide brand portfolio such as BiSeptol®, Calmotusin®, Emocalm®, Dacoderm®, etc..Dacia Plant realized a turnover of more than 10 million euros in 2021.
"I am very happy that we have come to an agreement with Dacia Plant. This acquisition fits perfectly within Ceres Pharma’s women and family health strategy. The demand for natural products is growing everywhere. With Dacia Plant we will reinforce our position in Romania and we can strengthen our product portfolio outside Romania with a broad range of Natural Phytotherapy Products”, says Mario Debel, CEO of Ceres Pharma.
The founders and co-CEO’s Calin Ioan Ianta and Radu Ionescu Heroiu will remain on board. “We are pleased to be part of a strong, dynamic and fast growing international group, such as Ceres Pharma. Together, we will be stronger to execute our ambitious growth plan in Romania and we will be able to sell our Natural Phytotherapy Products and new innovative product pipeline in other Western, Central and Eastern European countries.", says Calin Ioan Ianta, co-CEO of Dacia Plant.
About Dacia Plant
Dacia Plant is one of the pioneers and top 3 player in Romania active in the development, production and distribution of qualitative and innovative natural food supplements and vitamins.
About Ceres Pharma
Ceres Pharma is a dynamic and fast growing, Belgian based, pharmaceutical company, founded in 2017 by CEO Mario Debel and Alychlo and recently acquired in 2021 by Naxicap Partners. It is the ambition of Ceres Pharma to grow through the development of its own product portfolio as well as through acquisitions. Ceres Pharma is active in the development and distribution of drugs, medical devices, biocides, cosmetics, qualitative food supplements and pharmaceutical preparations in the Benelux and in Central and Eastern Europe.
About Naxicap Partners
As one of the top private equity firms in France, Naxicap Partners - an affiliate of Natixis Investment Managers - has €5 billion in assets under management. As a committed, responsible investor, Naxicap Partners builds solid, constructive partnerships with entrepreneurs so that their projects can succeed. The firm has 39 investment professionals spread across five offices in Paris, Lyon, Toulouse, Nantes and Frankfurt.